Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Small Cell Lung Cancer Clinical Trial

— NGR007  

Official title:

NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00483509
• Other study ID #: NGR007
• Secondary ID: 2006-005700-14
• Status: Completed
• Phase: Phase 2
• Start date: February 14, 2007
• Est. completion date: May 17, 2011

Study information

• Verified date: September 2019
• Source: MolMed S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic small cell lung carcinoma (SCLC) patients previously treated with at least one therapeutic regimen

Description:

This is a phase II, open-label, non-randomized study that will be conducted in patients affected by advanced or metastatic SCLC, previously treated with at least one therapeutic regimen, that will be conducted using Simon's two-stage design method.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: May 17, 2011
• Est. primary completion date: September 22, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years affected by SCLC previously treated with at least one therapeutic regimen (including doxorubicin). However, in case of patient already pretreated with doxorubicin, a previous cumulative dose of doxorubicin < 300 mg/m^2 is recommended and the current treatment has to be stopped when a maximum cumulative dose of doxorubicin 550 mg/m^2 is reached.

• Cytology or histology confirmed SCLC at first diagnosis (patient with recurrent disease do not require a confirmatory biopsy to be eligible)

• Measurable disease, defined as = 1 unidimensional measurable lesion = 20 mm by conventional techniques or = 10 mm by CT scan according to RECIST criteria

• ECOG Performance status 0 - 2

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

• Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

• Bilirubin < 1.5 x ULN

• AST and/or ALT < 2.5 x ULN in absence of liver metastasis

• AST and/or ALT < 5 x ULN in presence of liver metastasis

• Serum creatinine < 1.5 x ULN

• Normal cardiac function (LVEF = 55%) and absence of uncontrolled hypertension

• Patients may have had prior therapy providing the following conditions are met:

• Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days before start treatment

• Surgery: wash-out period of 14 days before start treatment

• Patients must give written informed consent to participate in the study

Exclusion Criteria:

• Concurrent anticancer therapy

• Patients may not receive any other investigational agents while on study

• Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication

• Uncontrolled hypertension

• Prolonged QTc interval (congenital or acquired)

• Patient with significant peripheral vascular disease

• Previous signs of cardiotoxicity doxorubicin related

• Clinical signs of CNS involvement

• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

• Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients

• Known hypersensitivity/allergic reaction or contraindications to anthracyclines

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

• Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• NGR-hTNF
iv q3W 0.8 mcg/sqm NGR-hTNF
• Doxorubicin
iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera Universitaria San Martino	Genoa
Italy	Istituto Nazionale per la Ricerca sul Cancro	Genoa
Italy	Fondazione San Raffaele del Monte Tabor	Milan
Italy	Azienda Ospedaliera Universitaria San Luigi Gonzaga	Orbassano	Turin
Italy	Istituto Clinico Humanitas	Rozzano	Milan

Sponsors (1)

Lead Sponsor	Collaborator
MolMed S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antitumour Activity Defined as Progression Free Survival (PFS)	Defined as the time from the date of randomization until disease progression, or death due to any cause or the last patient was known to be alive. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition the appearance of one or more new lesions was also considered progression	From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 150 weeks
Secondary	Tumor Growth Control Rate (TGCR)	evaluated according to Response evaluation criteria in solid tumors (RECIST V1.0) for target lesions and assessed by MRI: Complete Response (CR):Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the base line sum LD; Progressive Disease (PD): At least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.	Assessed every 6-12 weeks, up to 150 weeks
Secondary	Overall Survival (OS)	Overall Survival was defined as the time from the baseline CT scan to death due to any cause, or the last date the patient was known to be alive.	Through study completion, an average of 3 years
Secondary	Experimental Imaging Study (DCE-MRI)	To document possible modifications on vessels permeability by imaging techniques	during the study
Secondary	Number of Adverse Events, Reported by Severity and Relation to Treatment	Evaluation according to NCI common terminology criteria for adverse events (version 3.0)	Through study completion, an average of 3 years